Nanoparticle-Delivered EPA Reduces Liver Inflammation and Scarring in Rat Study
This laboratory study tested whether packaging EPA (an omega-3 fatty acid) into a tiny silica-based nanoemulsion could improve its effects on liver damage. Researchers used rats treated with a liver-damaging chemical (DEN) to trigger inflammation, oxidative stress, and early fibrosis, then compared plain EPA against the nanoemulsion version (EPA-NE).
Both EPA forms restored a healthier balance between omega-3 (EPA) and omega-6 (arachidonic acid) fatty acids in liver cell membranes, lowered blood homocysteine (a marker linked to inflammation), and reduced key inflammatory signaling markers (NF-κB and PKCα). They also boosted antioxidant activity (catalase) and reduced markers of oxidative damage (malondialdehyde), while increasing protective Nrf2 and miR-34a gene activity.
The nanoemulsion form of EPA consistently outperformed regular EPA across nearly every measure, including greater reductions in homocysteine, inflammation, and oxidative stress, along with better improvements seen under the microscope in liver tissue.
What this means for you
This is early-stage animal research, not a human clinical trial, so it can’t tell us how EPA or EPA-based nanoemulsions would work in people. However, it offers interesting scientific insight into how improving the delivery of EPA might enhance its known anti-inflammatory and antioxidant effects on liver tissue, an area worth watching for future human research.
Ready to start? The ALP Protocol delivers the EPA & DHA doses used in the research.
Start the ALP ProtocolSource
Naunyn-Schmiedeberg's archives of pharmacology · 2026-07-23 · DOI: 10.1007/s00210-026-05690-2
Read the original source ↗This summary is for educational purposes only and is not medical advice. Always talk to your healthcare provider before making changes to your supplement routine.